The Rise of Obesity Medications: Trends, Costs, and Accessibility

Women make up seven out of ten people receiving weight-loss medication in Sweden, according to recent data from Sveriges Radio, highlighting a significant gender disparity in the use of these treatments.

The finding comes from an analysis of prescription data showing that 70% of individuals prescribed obesity medications such as GLP-1 receptor agonists are women, a trend described by healthcare observers as reflecting greater interest among women in seeking medical intervention for weight management.

This pattern aligns with broader trends in obesity treatment utilization, where women have historically been more likely to seek care for weight-related concerns, though experts caution that biological, social, and healthcare access factors may all contribute to the disparity.

Meanwhile, the growing use of GLP-1 drugs like Ozempic and Wegovy is having measurable effects beyond individual health, including impacts on retail sectors. Svenska Dagbladet reported that the so-called “Ozempic wave” is influencing consumer behavior in the grocery industry, with early indications of shifted purchasing patterns as users experience reduced appetite and altered food preferences.

In related developments, Aftonbladet noted that newer obesity medications are becoming more affordable in Sweden due to changes in pricing and subsidy mechanisms, potentially increasing access for a broader population. However, specific details about the extent of cost reductions or eligibility criteria were not provided in the source.

These trends occur amid rising global spending on obesity treatments. A 2024 analysis cited by RxBenefits projected a potential 378% increase in net spending on obesity drugs, equivalent to $8.1 billion, driven largely by the expanded use of GLP-1 receptor agonists originally developed for type 2 diabetes but now widely prescribed off-label for weight loss.

The financial strain of these medications is also evident in employer-sponsored health plans. According to a 2024 survey by WTW referenced in HR Executive, more than half of employers (52%) reported covering GLP-1s for weight loss, despite ongoing concerns about costs, with these drugs continuing to drive a substantial portion of increases in pharmacy spending even after cost-containment strategies were implemented.

Further emphasizing the public health dimension, Dagens Nyheter published a commentary by Isobel Hadley-Kamptz questioning whether life-saving obesity care should be accessible only to those who can afford it, underscoring ongoing debates about equity in access to emerging treatments.

Region Gotland has also issued informational materials about treatment with new obesity medications, aiming to educate patients on proper use, expected outcomes, and potential side effects as part of broader efforts to support informed decision-making in clinical practice.

While GLP-1 drugs have demonstrated significant clinical benefits for weight reduction and cardiometabolic health, their high cost and expanding use for conditions like obstructive sleep apnea and diabetes continue to pose challenges for healthcare systems, insurers, and policymakers striving to balance innovation with affordability and equitable access.